NCT03579472: M7824 and Eribulin Mesylate in Treating Participants With Metastatic Triple Negative Breast Cancer

NCT03579472
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active, symptomatic central nervous system (CNS) metastases that require therapeutic intervention, including leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03579472

Comments are closed.

Up ↑